Patent ID: 9150903
Filing Date: 2015-10-06
Classification: A61K,C07K,C12Q,G01N

Abstract:
1. A method of converting an α2-antiplasmin molecule from a serine protease inhibitor to a serine protease substrate in a human patient in need thereof, comprising: a) selecting a monoclonal antibody for an ability to specifically bind to a human α2-antiplasmin molecule at a binding site to convert the human α2-antiplasmin molecule from a serine protease inhibitor to a serine protease substrate, b) determining an effective amount of the monoclonal antibody for increasing the conversion of the α2-antiplasmin molecule from the serine protease inhibitor to the serine protease substrate in the patient, and c) administering to the patient the effective amount of the selected monoclonal antibody, thereby increasing serine protease activity in the patient, wherein the effective amount of the selected monoclonal antibody administered to the patient to increase plasmin activity is less than an effective amount of an administered monoclonal antibody that has the ability to bind to the human α2-antiplasmin molecule but does not induce conversion of the human α2-antiplasmin molecule from a serine protease inhibitor to a serine protease substrate.